Cookies on this site

A new study, co-led by Professor Arjune Sen and supported by Nuffield Department of Clinical Neurosciences, aims to improve understanding of the risk factors, care pathways and broader health and social impacts of epilepsy in Nepal.

Woman with child in rural Nepal, walking away from the camera © Shutterstock

Epilepsy is one of the most common neurological disorders globally. According to the WHO, it affects over 50 million people with 80% of those living in low to middle income countries (LMICs). Additionally, around 15 million women of reproductive age live with epilepsy, making it the most common serious neurological condition encountered in pregnancy.

Epilepsy remains underdiagnosed, undertreated and poorly understood, particularly in LMICs, where there are shortages of neurologists, diagnostic tools and essential medications. Through the collection of comprehensive, standardised data on epilepsy and pregnancy outcomes, the MOMENTUM study will help inform national policy, shape culturally sensitive approaches to treatment and contribute to global efforts to address epilepsy and maternal health in countries, such as Nepal, where resource is limited.

Bringing together researchers from NDCN, Nuffield Department of Women’s and Reproductive Health, the Centre for Global Epilepsy and the Nepal Public Health Foundation (NPHF), the study will also build much needed research capacity in Nepal and strengthen international collaboration. 

 

The work planned will explore the vitally important intersections between seizure disorders and maternal health with a clear plan to improvements in brain health policy more broadly

 

Understanding the true burden

In Nepal, there is limited up-to-date data on the burden of epilepsy. A 2020 survey reported 8.5 cases of epilepsy per 1,000 people and an estimated 70-80% not receiving the treatment they need. The true burden of epilepsy has likely worsened given poor infrastructure, limited access to diagnostic tools, and continued lack of public awareness of the condition.

This study will generate the first dataset on epilepsy in Nepal in nearly two decades. At the National Academy of Medical Sciences (NAMS) and Paropakar Maternity and Women's Hospital in Kathmandu, the Global Epilepsy Research Database (GERD) questionnaire will be used to collect data, both from existing records and an ongoing study of new patient cohorts. It will also collect comprehensive, standardised data on epilepsy and pregnancy outcomes in Nepal

Interviews with affected individuals will explore lived experiences, providing deeper insights into cultural interpretations of epilepsy in the region. Stigma remains a major barrier to epilepsy treatment, with misconceptions about the condition preventing individuals from seeking appropriate help and contributing to a poor quality of life.  Additional mental disorders, such as anxiety and depression, are also common in people with epilepsy, yet these are often overlooked.

 

A focus on maternal health

Pregnant women with epilepsy face additional challenges, from increased risk of death during pregnancy or childbirth to complications such as pre-eclampsia, premature delivery and prolonged seizures. Furthermore, infants exposed to certain anti-seizure medications (ASMs) are at higher risk of congenital anomalies and neurodevelopmental delay.

The lack of data on pregnancy outcomes and the safe use of medications is a particular challenge in an environment where there is limited support to manage these risks and medical guidance is unclear.

Deepesha Silpakar speaks at Oxford Martin School, December 2025

As part of this collaboration, Ms Deepesha Silpakar, Project Coordinator at NPHF, recently joined the Centre for Global Epilepsy as an Oxford Martin School Visiting Fellow. In December 2025 she shared insights from her work at a talk examining how epilepsy is addressed within maternal health frameworks in Nepal.

Reflecting on her fellowship, Deepesha explained ‘I gained important insights into the existing gaps between research, policy, and practice in the care of women with epilepsy in Nepal, particularly during pregnancy. There is urgent need for clear clinical and policy guidelines that link epilepsy care with maternal health pathways to ensure quality of care for women throughout pregnancy, childbirth, and the postnatal period in Nepal.'

Professor Arjune Sen, Professor of Global Epilepsy at the University of Oxford, added ' It is both a delight and a privilege to be initiating the MOMENTUM project with Nepal Public Health Foundation, a core partner of the Centre for Global Epilepsy. The work planned will explore the vitally important intersections between seizure disorders and maternal health with a clear plan to improvements in brain health policy more broadly. It is also wonderful that The MOMENTUM project is being directly supported by research funds held in NDCN/CGE – a clear example of University of Oxford’s enduring commitment to positively empower epilepsy research and care worldwide.'

Similar stories

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Meeting the neuroscientists at Meeting Minds

Ben Seymour and Masud Husain joined the line up of speakers at this year's Meeting Minds event for Oxford alumni on 19 September

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Dr Ruxandra Dafinca awarded an Alzheimer’s Society Dementia Research Leader Fellowship

Ruxandra Dafinca is one of 17 early career researchers awarded a fellowship in the 2025/2026 call for her project focused on frontotemporal dementia.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.